P3 (Prepared, Protected, emPowered) (P3)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT03320512 |
Recruitment Status :
Completed
First Posted : October 25, 2017
Results First Posted : September 19, 2022
Last Update Posted : October 25, 2022
|
- Study Details
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Sexually Transmitted Diseases Safe Sex Adherence, Medication | Behavioral: P3 Behavioral: P3+ Behavioral: Control | Not Applicable |
Sustainable, integrated PrEP adherence interventions are critically needed to reduce HIV incidence among YMSM and YTW. It is imperative that the investigators develop adherence interventions for YMSM and YTW initiating PrEP that are engaging, age-appropriate and take advantage of technologies that are already embedded in these individual's lives. A smartphone-delivered PrEP adherence intervention is well suited for this population, given they have a high-uptake and utilization of smartphone technology. The use of smartphones to deliver HIV prevention and care interventions has grown substantially in recent years due to: a) wide-scale adoption of smartphone technology among high-risk groups, b) the ability to deliver interventions in real-time within risk contexts, and c) low implementation costs.The accessibility, affordability, anonymity and acceptability of smartphones make them the intervention medium of choice for engaging youth and a logical platform to deliver an adherence intervention targeting PrEP. Further, smartphone interventions address can overcome issues that impede engagement with in-person interventions such as transportation logistics, stigma and confidentiality. Further youth, including YMSM and YTW are receptive to smartphone delivered interventions and these interventions can impact HIV related prevention behaviors.
P3 (Prepared, Protected, emPowered) is an interactive smartphone app for HIV-uninfected YMSM and YTW that utilizes social networking and game-based mechanics as well as a comprehensive understanding of what constitutes "best practices" in app development to improve PrEP adherence and persistence in PrEP care. Built on a successful, evidence-based platform designed and tested by our collaborating technology partner, Ayogo, P3 is flexible and responsive to changes in technology. This flexibility will also allow us to quickly respond to and modify our intervention to align with emerging PrEP practice standards and guidelines.
Despite the benefits of app-based interventions, maintaining engagement over time can be particularly challenging. Lack of rapport building may contribute to lower retention rates in technology-based interventions. Further, the available literature suggests that some tools, including technology based tools, may be more beneficial to patient adherence when combined with education or counseling. To investigate this possibility, the investigators will include a study arm (P3+) that includes P3 and adherence counseling delivered by a counselor through the P3 app.
This study has three phases, usability testing, field testing, and a randomized-controlled trial (RCT). In usability testing the investigators will test beta versions of the app and gain feedback about the intervention from the target population, identify any technical issues, and get feedback on app content. Field testing is to ensure that the features, platform and content of P3 and P3+ are acceptable to the target population and that there are no technical challenges or user concerns with either the app, the dried blood spot (DBS), hair, or mitra sampling collection.
The last phase is a three arm, RCT that will test the efficacy of P3, a novel, theory-based mobile app that utilizes game mechanics and social networking features to improve PrEP adherence, retention in PrEP clinical care, and PrEP persistence among young men who have sex with men (YMSM) and young trans women (YTW) who have sex with men, ages 16-24. The investigators will test the efficacy of P3 and P3+, which adds Next Step Counseling delivered by an adherence counselor through the app, against PrEP standard of care. Participants will be randomized to P3, P3+, or standard of care. A cost comparison between P3 and P3+ will be conducted.
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 246 participants |
Allocation: | Randomized |
Intervention Model: | Factorial Assignment |
Intervention Model Description: | The trial will consist of a three-arm RCT to test intervention efficacy among young men who have sex with men (YMSM) and young transgender women who have sex with men (YTWSM) who are starting PrEP or are non-adherent to PrEP. Study arms will include P3, P3+, and standard of care (SOC). Participants will be recruited from seven cities. The investigators will enroll up to 240 participants and randomize them 1:1:1 to receive P3, P3+, or SOC. Assessments will be completed at months 0, 3, and 6. |
Masking: | None (Open Label) |
Primary Purpose: | Prevention |
Official Title: | P3 (Prepared, Protected, emPowered): Promoting Pre-exposure Prophylaxis (PrEP) Adherence Through a Social Networking, Gamification, and Adherence Support App |
Actual Study Start Date : | May 15, 2019 |
Actual Primary Completion Date : | September 16, 2021 |
Actual Study Completion Date : | September 16, 2021 |
Arm | Intervention/treatment |
---|---|
Experimental: P3
Participants will use P3
|
Behavioral: P3
P3 is an interactive smartphone app that utilizes social networking and game-based mechanics to improve PrEP adherence and persistence in PrEP care. The participant will install P3 on their phone, receive a guided tour of the app and a reminder card with the research coordinator's phone number and email address and instructed to contact the research coordinator immediately to report difficulties with any app components or to report any problems with their phone or phone service. A help link is embedded within the app that directly links to study staff if assistance is needed. P3 arm participants will have 24-hour access to all features of P3.
Other Name: Prepared, Protected, emPowered |
Experimental: P3+
Participants will use P3+
|
Behavioral: P3+
In P3+, participants receive all of P3 and the ability to text in the app with an adherence counselor, using Next Step Counseling (NSC). NSC is an interactive, client-centered motivational intervention to improve PrEP adherence. Key components of NSC include: review experiences with adherence, exploration of adherence facilitators and barriers, identification of adherence needs, identification of strategies to meet needs, and development of an adherence action plan. Participants will install P3+ on their phone. The adherence counselor feature will be unlocked for those in the P3+ arm. P3+ participants will have 24-hour access to all features of P3+. |
Placebo Comparator: Control
Participants will receive the standard of care
|
Behavioral: Control
Control participants will receive the standard of care for receiving a prescription for PrEP. |
- PrEP Adherence Defined by Tenofovir Diphosphate (P3 and P3+ vs Control) [ Time Frame: Month 3, Month 6 ]PrEP adherence is measured by blood sample levels of tenofovir diphosphate (TFV-DP) with blood concentration consistent with > 4 doses/week at 3- and 6- month follow-ups. The estimation of the average treatment effect compared P3 and P3+ combined to Control.
- PrEP Adherence Defined by Emtricitabine Triphosphate (P3 and P3+ vs Control) [ Time Frame: Month 3, Month 6 ]PrEP adherence is measured by blood sample levels of emtricitabine triphosphate (FTC-TP) with blood concentration consistent with > 4 doses/week at 3- and 6- month follow-ups. The estimation of the average treatment effect compared P3 and P3+ combined to Control.
- Number of Participants With Self-reported Retention in PrEP Clinical Care [ Time Frame: Month 3, Month 6 ]The investigators define "retention in care" as at least 1 PrEP clinical visit occurring in the last 3 months.
- PrEP Persistence [ Time Frame: Month 3, Month 6 ]PrEP persistence will be measured by self-report at follow up of current PrEP use.
- Insertive Condomless Anal Sex [ Time Frame: Month 3, Month 6 ]Sexual Practices were assessed by self-reported number of insertive condomless anal sex occurrences during the past 3 months. This question is asked at the 3- and 6-month follow-up surveys.
- Receptive Condomless Anal Sex [ Time Frame: Month 3, Month 6 ]Sexual Practices were assessed by self-reported number of receptive condomless anal sex occurrences during the past 3 months. This question is asked at the 3- and 6-month follow-up surveys.
- Sexually Transmitted Infections (STI) Incidence [ Time Frame: Month 3, Month 6 ]Self-reported STIs (combined rectal and urethral gonorrhea and chlamydia, syphilis) in last 3 months. This question is asked at the 3- and 6-month follow-up surveys.
- PrEP Adherence Defined by Tenofovir Diphosphate (P3 vs Control and P3+ vs Control) [ Time Frame: Month 3, Month 6 ]PrEP adherence is measured by blood sample levels of tenofovir diphosphate (TFV-DP) with blood concentration consistent with > 4 doses/week at 3- and 6- month follow-ups. The estimation of the average treatment effect compared P3 to Control and also P3+ to Control.
- PrEP Adherence Defined by Emtricitabine Triphosphate (P3 vs Control and P3+ vs Control) [ Time Frame: Month 3, Month 6 ]PrEP adherence is measured by blood sample levels of emtricitabine triphosphate (FTC-TP) with blood concentration consistent with > 4 doses/week at 3- and 6- month follow-ups. The estimation of the average treatment effect compared P3 to Control and also P3+ to Control.
- Self-Reported Weekly PrEP Use [ Time Frame: Month 3, Month 6 ]Number of participants reported taking their PrEP medication >/= 4 days in the past week.
- Self-Reported Monthly PrEP Use [ Time Frame: Month 3, Month 6 ]Median self-reported percent of time in the past month that participants' took their PrEP as prescribed.
- Mean Site-Level Intervention Cost [ Time Frame: Throughout the duration of the study, approximately 1.5 years ]Information was collected on (1) time spent by study staff for training and supervision of adherence counselor(s); (2) time participants spent in the adherence counseling sessions; and (3) costs associated with the delivery of both P3 and P3+. Resources were organized into standard expenditure categories and attributed to the corresponding P3 or P3+ arm and study site as appropriate.

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 16 Years to 24 Years (Child, Adult) |
Sexes Eligible for Study: | Male |
Gender Based Eligibility: | Yes |
Gender Eligibility Description: | Self-identify as MSM or TW who has sex with men |
Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
- Are aged 16-24
- Were assigned male sex at birth
- Report sex with men or transgender women
- Are able to speak and read English
- Have reliable daily access to an Android or iOS smartphone with a data plan
- Are HIV-uninfected (self-report)
- Are not currently on PrEP but plan to initiate in the next 7 days and have an active PrEP prescription (prescription confirmed by study staff) OR on PrEP have an active PrEP prescription (prescription confirmed by study staff)
- Recruited from one of 9 subject recruitment venues (SRV) cities (Atlanta, Georgia; Boston, Massachusetts; Bronx, New York; Chicago, Illinois; Houston, Texas; Philadelphia, Pennsylvania; Tampa, Florida; Chapel Hill, NC; Charlotte, NC)
Exclusion Criteria:
- Aged younger than 15 years or older than 24 years
- Not available to meet with project staff for planned study visit(s)
- Non-English speaking
- Living with HIV
- Not currently prescribed PrEP (study staff unable to verify participant has an active PrEP prescription by a health provider)
- Anticipate not having reliable access to a smartphone with a data plan for 2 or more days during field testing or 1 or more weeks during the RCT intervention period
- Planning to move out of study area during the study period
- Unwilling or unable to comply with protocol requirements.
- Participated in field trial phase of P3 study
- Unable to be consented due to active substance use or psychological condition.

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03320512
United States, Florida | |
University of South Florida Infectious Diseases | |
Tampa, Florida, United States, 33606 | |
United States, Georgia | |
PRISM Health | |
Atlanta, Georgia, United States, 30322 | |
United States, Illinois | |
The Adolescent and Young Adult Research (AYAR) at the CORE Center | |
Chicago, Illinois, United States, 60612 | |
United States, Massachusetts | |
The Fenway Institute | |
Boston, Massachusetts, United States, 02215 | |
United States, New York | |
Children's Hospital at Montefiore | |
Bronx, New York, United States, 10467 | |
United States, North Carolina | |
UNC-Chapel Hill | |
Chapel Hill, North Carolina, United States, 27599 | |
RAIN | |
Charlotte, North Carolina, United States, 29202 | |
United States, Pennsylvania | |
Adolescent Initiative at Children's Hospital of Philadelphia | |
Philadelphia, Pennsylvania, United States, 19104 | |
United States, Texas | |
Texas Children's Hospital | |
Houston, Texas, United States, 77030 |
Principal Investigator: | Lisa Hightow-Weidman, MD | UNC Chapel Hill |
Documents provided by University of North Carolina, Chapel Hill:
Responsible Party: | University of North Carolina, Chapel Hill |
ClinicalTrials.gov Identifier: | NCT03320512 |
Other Study ID Numbers: |
17-1951 5U19HD089881-02 ( U.S. NIH Grant/Contract ) |
First Posted: | October 25, 2017 Key Record Dates |
Results First Posted: | September 19, 2022 |
Last Update Posted: | October 25, 2022 |
Last Verified: | August 2022 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | No |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | No |
PrEP gamification mHealth HIV prevention truvada |
eHealth app adherence ymsm transgender women |
Sexually Transmitted Diseases Communicable Diseases Infections Genital Diseases |
Urogenital Diseases Disease Attributes Pathologic Processes |